JP6449482B2 - 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用 - Google Patents
縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用 Download PDFInfo
- Publication number
- JP6449482B2 JP6449482B2 JP2017550129A JP2017550129A JP6449482B2 JP 6449482 B2 JP6449482 B2 JP 6449482B2 JP 2017550129 A JP2017550129 A JP 2017550129A JP 2017550129 A JP2017550129 A JP 2017550129A JP 6449482 B2 JP6449482 B2 JP 6449482B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- mmol
- general formula
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C)C(C)=S(C)(C)**1(*)C*CCC1 Chemical compound C*(C)C(C)=S(C)(C)**1(*)C*CCC1 0.000 description 9
- MHKHZUBCUZCADO-UHFFFAOYSA-N CN(C(C(O)=O)=O)c(cc1)cc2c1cncc2-c(cc1)c(cccc2)c2c1C#N Chemical compound CN(C(C(O)=O)=O)c(cc1)cc2c1cncc2-c(cc1)c(cccc2)c2c1C#N MHKHZUBCUZCADO-UHFFFAOYSA-N 0.000 description 1
- DKQXXCORCHGPPV-CYBMUJFWSA-N C[C@H](CC(O)=O)c1cc(cncc2-c(c3ccccc33)ccc3C#N)c2[s]1 Chemical compound C[C@H](CC(O)=O)c1cc(cncc2-c(c3ccccc33)ccc3C#N)c2[s]1 DKQXXCORCHGPPV-CYBMUJFWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/36—Benzo-cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510131828 | 2015-03-24 | ||
| CN201510131828.5 | 2015-03-24 | ||
| PCT/CN2016/073043 WO2016150255A1 (zh) | 2015-03-24 | 2016-02-01 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509451A JP2018509451A (ja) | 2018-04-05 |
| JP2018509451A5 JP2018509451A5 (https=) | 2018-07-05 |
| JP6449482B2 true JP6449482B2 (ja) | 2019-01-09 |
Family
ID=56977003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550129A Active JP6449482B2 (ja) | 2015-03-24 | 2016-02-01 | 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10100015B2 (https=) |
| EP (1) | EP3275867B1 (https=) |
| JP (1) | JP6449482B2 (https=) |
| KR (1) | KR102087918B1 (https=) |
| CN (3) | CN106008340B (https=) |
| AU (1) | AU2016236669B2 (https=) |
| CA (1) | CA2980484C (https=) |
| IL (1) | IL254098B (https=) |
| MX (1) | MX383376B (https=) |
| NZ (1) | NZ735044A (https=) |
| RU (1) | RU2683566C1 (https=) |
| SG (1) | SG11201706869XA (https=) |
| TW (2) | TWI675026B (https=) |
| WO (1) | WO2016150255A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016236669B2 (en) | 2015-03-24 | 2018-11-08 | Shanghai Yingli Pharmaceutical Co., Ltd | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
| WO2017012559A1 (zh) * | 2015-07-21 | 2017-01-26 | 广州再极医药科技有限公司 | 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| US10829483B2 (en) * | 2016-05-23 | 2020-11-10 | Cstone Pharmaceutical (Suzhou) Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
| CN106146533B (zh) * | 2016-07-14 | 2018-04-03 | 华润赛科药业有限责任公司 | 含硫杂环羧酸类衍生物、其制备方法和应用 |
| CN106083847B (zh) * | 2016-08-03 | 2018-10-30 | 山东大学 | 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用 |
| WO2018090921A1 (zh) * | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108033909A (zh) * | 2017-12-20 | 2018-05-15 | 北京六合宁远科技有限公司 | 一种6-甲基-4-溴-异喹啉的制备方法 |
| CN109608432B (zh) * | 2018-12-17 | 2022-10-11 | 江苏艾立康医药科技有限公司 | 作为urat1抑制剂的噻吩类衍生物 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN111303161B (zh) * | 2020-04-14 | 2021-01-05 | 遵义医科大学珠海校区 | 嘧啶并氮杂环类化合物及其用途 |
| CN111763218B (zh) * | 2020-07-14 | 2021-05-28 | 山东大学 | 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用 |
| US20250059202A1 (en) | 2022-01-04 | 2025-02-20 | Shanghai Yingli Pharmaceutical Co., Ltd | Crystal form of fused ring derivative, and preparation method therefor and use thereof |
| CN116465985B (zh) * | 2023-03-03 | 2024-12-10 | 连云港杰瑞药业有限公司 | 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法 |
| EP4688750A1 (en) | 2023-04-06 | 2026-02-11 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| CN118955327A (zh) * | 2024-06-26 | 2024-11-15 | 安徽大学 | 一种4-溴-1-萘甲腈的合成方法 |
| CN118878551B (zh) * | 2024-07-08 | 2026-04-28 | 安徽大学 | 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558655A (en) * | 1969-06-25 | 1971-01-26 | Parke Davis & Co | Benzo(b)thiopheneacetic acid compounds |
| US4224330A (en) | 1979-09-13 | 1980-09-23 | Zoecon Corporation | Esters and thiolesters of benzothienyl acids |
| AUPO282896A0 (en) * | 1996-10-07 | 1996-10-31 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
| AU7031500A (en) | 1999-09-23 | 2001-04-24 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| WO2005063828A1 (en) * | 2003-12-22 | 2005-07-14 | Basell Polyolefine Gmbh | Metallocene compounds |
| SE0400440D0 (sv) * | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Cinnamic Amides |
| GB0426313D0 (en) * | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| US8916550B2 (en) * | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| US20090012097A1 (en) * | 2006-01-30 | 2009-01-08 | Irm Llc | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators |
| JPWO2007105753A1 (ja) | 2006-03-16 | 2009-07-30 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| JP2011520809A (ja) * | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
| US8809382B2 (en) * | 2009-05-04 | 2014-08-19 | The Royal Institution For The Advancement Of Learning/Mcgill University | 5-oxo-ETE receptor antagonist compounds |
| TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
| US8969349B2 (en) * | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| BR112012032193A2 (pt) * | 2010-06-16 | 2019-09-24 | Ardea Biosciences Inc | composto, composiçoes e métodos de uso de feniltioacetato |
| PE20141002A1 (es) | 2010-10-27 | 2014-08-17 | Bayer Ip Gmbh | Derivados de heteroarilpiperidina y -piperazina como fungicidas |
| DK2669270T3 (en) * | 2011-01-28 | 2018-02-26 | Sato Pharma | Indole-related compounds such as URAT1 inhibitors |
| US8957203B2 (en) * | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| WO2014017643A1 (ja) * | 2012-07-27 | 2014-01-30 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
| CN104812387A (zh) * | 2012-11-20 | 2015-07-29 | 霍夫曼-拉罗奇有限公司 | 取代的1,6-萘啶 |
| CN105163727B (zh) * | 2013-05-03 | 2018-08-17 | 豪夫迈·罗氏有限公司 | 刺激神经发生的异喹啉衍生物 |
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| BR112017013465A2 (pt) * | 2014-12-24 | 2018-03-06 | Lg Chem, Ltd | derivado de biarila, e, composição farmacêutica. |
| AU2016236669B2 (en) | 2015-03-24 | 2018-11-08 | Shanghai Yingli Pharmaceutical Co., Ltd | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
-
2016
- 2016-02-01 AU AU2016236669A patent/AU2016236669B2/en active Active
- 2016-02-01 MX MX2017012009A patent/MX383376B/es unknown
- 2016-02-01 CN CN201610071297.XA patent/CN106008340B/zh active Active
- 2016-02-01 CN CN201810188236.0A patent/CN108516958B/zh active Active
- 2016-02-01 SG SG11201706869XA patent/SG11201706869XA/en unknown
- 2016-02-01 RU RU2017134044A patent/RU2683566C1/ru active
- 2016-02-01 CN CN201810188235.6A patent/CN108299425B/zh active Active
- 2016-02-01 EP EP16767632.9A patent/EP3275867B1/en active Active
- 2016-02-01 NZ NZ735044A patent/NZ735044A/en unknown
- 2016-02-01 WO PCT/CN2016/073043 patent/WO2016150255A1/zh not_active Ceased
- 2016-02-01 US US15/559,181 patent/US10100015B2/en active Active
- 2016-02-01 KR KR1020177029920A patent/KR102087918B1/ko active Active
- 2016-02-01 JP JP2017550129A patent/JP6449482B2/ja active Active
- 2016-02-01 CA CA2980484A patent/CA2980484C/en active Active
- 2016-03-24 TW TW105109178A patent/TWI675026B/zh active
- 2016-03-24 TW TW106139600A patent/TWI666201B/zh active
-
2017
- 2017-08-22 IL IL254098A patent/IL254098B/en active IP Right Grant
-
2018
- 2018-05-22 US US15/985,848 patent/US10100016B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX383376B (es) | 2025-03-13 |
| IL254098B (en) | 2020-03-31 |
| CN106008340B (zh) | 2020-03-17 |
| CN108299425B (zh) | 2020-09-18 |
| EP3275867A4 (en) | 2018-01-31 |
| CA2980484A1 (en) | 2016-09-29 |
| AU2016236669A1 (en) | 2017-09-21 |
| CN108516958B (zh) | 2020-07-17 |
| TW201641491A (zh) | 2016-12-01 |
| TW201808909A (zh) | 2018-03-16 |
| HK1226055A1 (zh) | 2017-09-22 |
| CN106008340A (zh) | 2016-10-12 |
| KR20170123705A (ko) | 2017-11-08 |
| EP3275867B1 (en) | 2020-06-10 |
| TWI666201B (zh) | 2019-07-21 |
| NZ735044A (en) | 2018-10-26 |
| CN108299425A (zh) | 2018-07-20 |
| TWI675026B (zh) | 2019-10-21 |
| AU2016236669B2 (en) | 2018-11-08 |
| EP3275867A1 (en) | 2018-01-31 |
| KR102087918B1 (ko) | 2020-03-12 |
| CN108516958A (zh) | 2018-09-11 |
| WO2016150255A1 (zh) | 2016-09-29 |
| RU2683566C1 (ru) | 2019-03-29 |
| JP2018509451A (ja) | 2018-04-05 |
| US10100016B2 (en) | 2018-10-16 |
| US20180072678A1 (en) | 2018-03-15 |
| SG11201706869XA (en) | 2017-09-28 |
| CA2980484C (en) | 2019-11-26 |
| US10100015B2 (en) | 2018-10-16 |
| MX2017012009A (es) | 2018-06-06 |
| IL254098A0 (en) | 2017-10-31 |
| US20180265476A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6449482B2 (ja) | 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用 | |
| EP3927693B1 (en) | 2-phenyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile derivatives and similar compounds as thyroid hormone receptor agonists for the treatment of e.g. obesity | |
| TWI853806B (zh) | 小分子pd-1/pd-l1抑制劑、其與pd-l1抗體的藥物組合物及其應用 | |
| KR101720824B1 (ko) | 카테콜 ｏ-메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도 | |
| KR20210089195A (ko) | 비페닐계 화합물, 이의 중간체, 제조 방법, 약학 조성물 및 용도 | |
| KR101761963B1 (ko) | 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도 | |
| JP7561978B2 (ja) | ベンザミド類化合物及びその使用 | |
| JP2022504620A (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| US20220168268A1 (en) | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same | |
| JP2022515787A (ja) | 末端アミン基にアリールまたはヘテロアリール基が置換された新規なヒドラゾン誘導体及びその用途 | |
| TWI817191B (zh) | 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途 | |
| JP6671382B2 (ja) | 特に糖尿病の治療に有用である２−（１，２，４−トリアゾール−３−イルスルファニル）−ｎ−１，３，４−チアジアゾール−２−イルアセトアミドの誘導体 | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| RU2808433C1 (ru) | Новое биарильное производное, применяемое в качестве ингибитора диацилглицерол-ацилтрансферазы 2, и его применение | |
| CN118852164A (zh) | Parp选择性抑制剂 | |
| WO2025064325A1 (en) | Gpr35 modulators | |
| HK1226055B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| KR20190043013A (ko) | 신규한 인다졸 유도체 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170922 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20170922 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180521 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181002 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20181018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6449482 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |